AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas

Neuro-Oncology

Volumn 13, Issue 9, 2011, Pages 983-999

  Bush, Matthew L ^a   Oblinger, Janet ^a,b   Brendel, Victoria ^a   Santarelli, Griffin ^c   Huang, Jie ^a,b   Akhmametyeva, Elena M ^a,b   Burns, Sarah S ^a,b   Wheeler, Justin ^d   Davis, Jeremy ^d   Yates, Charles W ^a   Chaudhury, Abhik R ^a   Kulp, Samuel ^a   Chen, Ching Shih ^a   Chang, Long Sheng ^a,b   Welling, D Bradley ^a   Jacob, Abraham ^a,e  

^a OHIO STATE UNIVERSITY   (United States)

^b THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c MEDICAL COLLEGE OF OHIO   (United States)

^d THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Akt; AR42; Cell cycle arrest; HDAC inhibitors (HDACis); Meningiomas; Merlin; Neurofibromatosis type 2 (NF2); NF2 gene; Vestibular schwannomas (VS)

Indexed keywords

AR 42; HISTONE DEACETYLASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ACOUSTIC NEURINOMA; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MENINGIOMA; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FLUORESCENT ANTIBODY TECHNIQUE; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNOENZYME TECHNIQUES; MAGNETIC RESONANCE IMAGING; MENINGEAL NEOPLASMS; MENINGIOMA; MICE; MICE, KNOCKOUT; MICE, SCID; NEUROFIBROMATOSIS 2; NEUROFIBROMIN 2; NEUROMA, ACOUSTIC; PHENYLBUTYRATES; PHOSPHORYLATION; PROTEIN ARRAY ANALYSIS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SURVIVAL RATE;

EID: 80052766987     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor072     Document Type: Article

References (84)

1. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature. 1993;363(6429):515-521. (Pubitemid 23186636)
2. Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell. 1993;72(5):791-800. (Pubitemid 23093886)
3. Perry A, Louis DN, Scheithauer BW, et al. Meningiomas. In: Louis, D.N., Ohgaki, H., Wiestler, O.D., Cavenee, W.K., eds. WHO classification of tumours of the central nervous system. Lyon, France: IARC Press; 2007:164-172.
4. Son EI, Kim IM, Kim SP. Vestibular schwannoma with malignant transformation: a case report. J Korean Med Sci. 2001;16(6): 817-821.
5. Evans DG, Huson SM, Donnai D, et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counselling. J Med Genet. 1992;29:847-852. (Pubitemid 23035206)
6. Gutmann DH, Giordano MJ, Fishback AS, et al. Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas. Neurology. 1997;49:267-270. (Pubitemid 27328718)
7. Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. J Neurooncol. 2010;99(3):307-314. Epub 2010 Sep 7.
8. Welling DB, Packer MD, Chang LS. Molecular studies of vestibular schwannomas: a review. Curr Opin Otolaryngol Head Neck Surg. 2007;15(5):341-346. (Pubitemid 47373981)
9. Matthies C, Samii M. Management of 1000 vestibular schwannomas (acoustic neuromas): clinical presentation. Neurosurgery. 1997;40(1): 1-9; discussion 9-10.
10. Sauvaget E, Kici S, Kania R, et al. Sudden sensorineural hearing loss as a revealing symptom of vestibular schwannoma. Acta Otolaryngol. 2005;125(6):592-595. (Pubitemid 40874173)
11. Nageris BI, Popovtzer A. Acoustic neuroma in patients with completely resolved sudden hearing loss. Ann Otol Rhinol Laryngol. 2003;112(5):395-397. (Pubitemid 36617549)
12. Kameda K, Shono T, Hashiguchi K, et al. Effect of tumor removal on tinnitus in patients with vestibular schwannoma. J Neurosurg. 2010; 112(1):152-157.
13. Evans DG. Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis. 2009;4:16.
14. Levine EM, Becker Y, Boone CW, et al. Contact inhibition, macromolecular synthesis, and polyribosomes in cultured human diploid fibroblasts. Proc Natl Acad Sci USA. 1965;53:350-356.
15. Levine BB. Studies on delayed hypersensitivity. I. Inferences on the comparative binding affinities of antibodies mediating delayed and immediate hypersensitivity reactions in the guinea pig. J Exp Med. 1965;121:873-888.
16. Eagle H, Levine EM, Boone CW. Cellular growth, contact inhibition, and macromolecular synthesis. Science. 1965;148(3670):665.
17. Jacob A, Lee T, Neff BA, et al. Phosphatidylinositol 3-kinase/Akt pathway activation in human vestibular schwannoma. Otol Neurotol. 2008;29:58-68.
18. Mawrin C, Sasse T, Kirches E, et al. Different activation of mitogenactivated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas. Clin Cancer Res. 2005;11(11): 4074-4082. (Pubitemid 40791571)
19. Lee TX, Packer MD, Huang J, et al. Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells. Eur J Cancer. 2009;45(9): 1709-1720.
20. Johnson MD, Okediji E, Woodard A, et al. Evidence for phosphatidylinositol 3-kinase Akt-p70S6K pathway activation and transduction of mitogenic signals by platelet derived growth factor in human meningioma cells. J Neurosurg. 2002;97:668-675. (Pubitemid 34994385)
21. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006; 6:38-51. (Pubitemid 43054973)
22. Jung M. Inhibitors of histone deacetylase as new anticancer agents. Curr Med Chem. 2001;8:1505-1511. (Pubitemid 32894012)
23. Wade PA. Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. Hum Mol Genet. 2001;10:693-698. (Pubitemid 32331577)
24. Glaser KB, Staver MJ,Waring JF, et al. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther. 2003;2:151-163.
25. Villar-Garea A, Esteller M. Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int J Cancer. 2004;112: 171-178. (Pubitemid 39244355)
26. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell. 2003; 4:13-18. (Pubitemid 36904157)
27. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol. 2007;25:84-90. (Pubitemid 46087907)
28. Marks PA, Richon VM, Rifkind RA. Cell cycle regulatory proteins are targets for induced differentiation of transformed cells: molecular and clinical studies employing hybrid polar compounds. Int J Hematol. 1996;63:1-17. (Pubitemid 26037266)
29. Nimmanapalli R, Fuino L, Stobaugh C, et al. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood. 2003;101:3236-3239. (Pubitemid 36858020)
30. Ungerstedt JS, Sowa Y, XuW S, et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A. 2005;102:673-678. (Pubitemid 40282724)
31. Xu W, Ngo L, Perez G, et al. Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci U S A. 2006;103:15540-15545. (Pubitemid 44625628)
32. Marks PA, Dokmanovic M. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs. 2005;14:1497-1511. (Pubitemid 41749195)
33. Rosato RR, Maggio SC, Almenara JA, et al. The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide. Mol Pharmacol. 2006;69:216-225. (Pubitemid 43048908)
34. Santini V, Gozzini A, Ferrari G. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Current Drug Metabolism. 2007;8:383-394. (Pubitemid 46780066)
35. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5:769-784. (Pubitemid 44348499)
36. Drummond DC, Noble CO, Kirpotin DB, et al. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol. 2005;45:495-528. (Pubitemid 40261815)
37. Furchert SE, Lanvers-Kaminsky C, Juurgens H, et al. Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer. 2007;120(8):1787-1794. (Pubitemid 46399367)
38. Shu Q, Antalffy B, Su JMF, et al. Valproic acid prolongs survival time of severe combined immunodeficiency mice bearing intracerebellar orthotopic medulloblastoma xenografts. Clin Cancer Res. 2006;12: 4687-4694. (Pubitemid 44297822)
39. Li XN, Shu Q, Su JM, et al. Valproic acid induces growth arrest apoptosis, and senescence in medulloblastoma by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol Cancer Ther. 2005;4(12):1912-1922. (Pubitemid 43056974)
40. Papi A, Ferreri AM, Rocchi P, et al. Epigenetic modifiers as anticancer drugs: effectiveness of valproic acid in neural crest-derived tumor cells. Anticancer research. 2010;30:535-540.
41. Knupfer MM, Hernaiz-Driever P, Poppenborg H, et al. Valproic acid inhibits proliferation and changes expression of CD44 and CD56 of malignant glioma cells in vitro. Anticancer Res. 1998;18: 3585-3589. (Pubitemid 28546494)
42. Sharma V, Koul N, Joseph C, et al. HDAC inhibitor, scriptaid induces glioma cell apoptosis through JNK activation and inhibits telomerase activity. J Cell Mol Med. 2010;14(8):2151-2161.
43. Chen CS, Weng SC, Tseng PH, et al. Histone acetylation- independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. Bio Chem. 2005;280(46): 38879-38887.
44. Bai LY, Omar HA, Chiu CF, et al. Antitumor effects of (S)- HDAC42, a phenylbutryate-derived histone deacetylase inhibitor, in multiple myeloma cells. Cancer Chemother Pharmacol. 2010;(Epub):1-8.
45. Sargeant AM, Rengel RC, Kulp SK, et al. OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model. Cancer Res. 2008;68(10):3999-4009.
46. Lin TY, Fenger J, Murahari S, et al. AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant cell lines via down-regulation of constitutively activated Kit. Blood. 2010;115(21): 4217-4225.
47. Kulp SK, Chen CS, Wang DS, et al. Antitumor effects of a novel phenylbutyrate- based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer. Clin Cancer Res. 2006;12(17):5199-5206. (Pubitemid 44453349)
48. Lu YS, Kashida Y, Kulp SK, et al. Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. Hepatology. 2007;46(4): 1119-1130. (Pubitemid 350144776)
49. Yang YT, Balch C, Kulp SK, et al. A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer. Neoplasia. 2009;11(6):552-563.
50. Giovannini M, Robanus-Maandag E, van der Valk M, et al. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev. 2000;14(13): 1617-1630. (Pubitemid 30460911)
51. Chang LS, Akhmametyeva EM, Wu Y, et al. Multiple transcription initiation sites, alternative splicing, and differential polyadenylation contribute to the complexity of human neurofibromatosis 2 transcripts. Genomics. 2002;79(1):63-76. (Pubitemid 34112068)
52. John MR, Wickert H, Zaar K, et al. A case of neuroendocrine oncogenic osteomalacia associated with a PHEX and fibroblast growth factor-23 expressing sinusidal malignant schwannoma. Bone. 2001;29:393-402. (Pubitemid 32930068)
53. Püttmann S, Senner V, Braune S, et al. Establishment of a benign meningioma cell line by hTERT-mediated immortalization. Lab Invest. 2005;85(9):1163-1171. (Pubitemid 43073988)
54. Klampfer L, Huang J, Shirasawa S, et al. Histone deacetylase inhibitors induce cell death selectively in cells that harbor activated kRasV12: the role of signal transducers and activators of transcription 1 and p21. Cancer Res. 2007;67:8477-8485. (Pubitemid 47437421)
55. Plotkin SR, Halpin C, McKenna MJ, et al. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol Neurotol. 2010;31(7):1135-1143.
56. Evans DG, Kalamarides M, Hunter-Schaedle K, et al. Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. Clin Cancer Res. 2009;15(16):5032-5039.
57. Ammoun S, Cunliffe CH, Allen JC, et al. ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Neuro Oncol. 2010;12(8):834-843.
58. Plotkin SR, Stemmer-Rachamimov AO, Barker FG, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med. 2009;361(4):358-67.
59. Hilton DA, Ristic N, Hanemann CO. Activation of ERK, AKT and JNK signalling pathways in human schwannomas in situ. Histopathology. 2009;55(6):744-749.
60. Kaempchen K, Mielke K, Utermark T, et al. Upregulation of the Rac/ JNK1 signaling pathway in primary human schwannoma cells. Hum Mol Genet. 2003;12(11):1211-1221. (Pubitemid 36722601)
61. Shaw RJ, Paez JG, Curto M, et al. The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev Cell. 2001;1(1):63-72. (Pubitemid 33586069)
62. Scoles DR. The merlin interacting proteins reveal multiple targets for NF2 therapy. Biochim Biophys Acta,. 2008;1785(1):32-54. (Pubitemid 350192083)
63. Curto M, McClatchey AI. Nf2/Merlin: a coordinator of receptor signaling and intercellular contact. Br J Cancer. 2008;98(2):256-262. (Pubitemid 351161230)
64. Maitra S, Kulikauskas RM, Gavilan H, et al. The tumor suppressors Merlin and Expanded function cooperatively to modulate receptor endocytosis and signaling. Curr Biol. 2006;16(7):702-709.
65. Curto M, Cole BK, Lallemand D, et al. Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. J Cell Biol. 2007;177(5):893-903. (Pubitemid 46873094)
66. James MF, Beauchamp RL, Manchanda N et al. A NHERF binding site links the betaPDGFR to the cytoskeleton and regulates cell spreading and migration. J Cell Sci. 2004;117(Pt 14):2951-2961. (Pubitemid 39117670)
67. McClatchey AI, Fehon RG. Merlin and the ERM proteins-regulators of receptor distribution and signaling at the cell cortex. Trends Cell Biol. 2009;19(5):198-206.
68. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008;22(10): 1276-1312. (Pubitemid 351717519)
69. Li W, Nishimura R, Kashishian A, et al. A new function for a phosphotyrosine phosphatase: linking GRB2-Sos to a receptor tyrosine kinase. Mol Cell Biol. 1994;14(1):509-517.
70. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev. 2004;68(2):320-344. (Pubitemid 38756868)
71. Treisman R. Regulation of transcription by MAP kinase cascades. Curr Opin Cell Biol. 1996;8(2):205-215. (Pubitemid 26109094)
72. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005;24(50):7455-7464. (Pubitemid 41637985)
73. Coffer PJ, Jin J, Woodgett JR. Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J. 1998;335(Pt 1):1-13. (Pubitemid 28477043)
74. Johnson MD, O'Connell M, Vito F, et al.. Increased STAT-3 and synchronous activation of Raf-1-MEK-1-MAPK, and phosphatidylinositol 3- Kinase-Akt-mTOR pathways in atypical and anaplastic meningiomas. J Neurooncol. 2009;92(2):129-136.
75. Johnson M, Toms S. Mitogenic signal transduction pathways in meningiomas: novel targets for meningioma chemotherapy? J Neuropathol Exp Neurol. 2005;64(12):1029-1036.
76. Jin HO, Park IC, An S, et al. Up-regulation of Bak and Bim via JNK downstream pathway in the response to nitric oxide in human glioblastoma cells. J Cell Physiol. 2006;206:477-786.
77. Xia S, Li Y, Rosen EM, et al. Ribotoxic stress sensitizes glioblastoma cells to death receptor induced apoptosis: requirements for c-Jun NH2-terminal kinase and Bim. Mol Cancer Res. 2007;5: 783-792. (Pubitemid 47294806)
78. Dai Y, Rahmani M, Dent P, et al. Blockade of histone deacetylase inhibitor induced RelA/p65 acetylation and NFkappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol Cell Biol. 2005;25: 5429-5444. (Pubitemid 40853579)
79. Minden A, Lin A, McMahon M, et al. Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. Science. 1994;266:1719-1723.
80. Cress WD, Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol. 2000;184:1-16. (Pubitemid 30349623)
81. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001;1:194-202. (Pubitemid 33741894)
82. Lee EJ, Lee BB, Kim SJ, Park YD, Park J, Kim DH. Histone deacetylase inhibitor scriptaid induces cell cycle arrest and epigenetic change in colon cancer cells. International Journal of Oncology. 2008;33:767-776.
83. Lucas DM, Alinari L, West DA, et al. The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo. PLoS One. 2010;5(6):e10941.
84. Johnson MD, O'Connell M, Pilcher W. Lopinavir inhibits meningioma cell proliferation by Akt independent mechanism. J Neurooncol. 2011;101(3):441-448.